The combination of Keytruda and Padcev is taking another major step toward securing its position as a leading therapy in the ...

“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of ...

Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as a perioperative therapy for ...

Following the positive outcome, Pfizer and Astellas will seek approval of Padcev-Keytruda in MIBC regardless of a patient’s ...

Bladder cancer is the ninth most common cancer worldwide, diagnosed in more than 614,000 patients each year globally. 1 MIBC represents approximately 30% of all bladder cancer cases. 2 The standard ...

Merck says Keytruda plus Padcev improved survival and response rates versus chemotherapy in a Phase 3 muscle-invasive bladder ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase ...

PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder ...

Merck MRK announced that the FDA has approved both the intravenous (“IV”) and the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), each in ...

First and only systemic therapy to improve survival when used before and after surgery for patients with MIBC who are ineligible for cisplatin-based chemotherapy First ever positive Phase 3 study in ...

TOKYO and NEW YORK, Oct. 18, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced positive results from the ...